| A Follow up Study on Comparison of Therapeutic
Response of Bisphosphonates in Management of
Osteoporotic Vertebral Compression Fracture |
|
Bong Gil Seok , Jung Yul Park , Tae Young Cho, Dong Jun Lim , Sang Dae Kim |
|
Department of Neurosurgery, Korea University Medical Center, Ansan Hospital, Korea |
|
|
| Abstract |
Objective
Osteoporotic fractures are widely recognized as common and important causes of morbidity and
mortality among elderly. The aim of this study was to compare the effects of bisphosphonates, namely alendronate
and rispedronate, for the treatment on osteoporotic vertebral compression fracture (OVCF).
Materials
& Methods: A total of 245 patients were randomly divided into two groups; one with alendrnate treatment
and the other with risperdronate treatment. This is an extension of previous study in which data from 74 patients
were added to match the groups. Patients in Group A were allowed to take alandronate (70 mg/week) and patients
in Group B with risedronate (30 mg/week). The follow up duration was at least 6 months. The efficacy of the treatment
was evaluated by BMD measurements at spine and hip at 6 months and the degrees of compression fractures that
were newly developed or were aggravated during study period. The statistical analysis was done by SPSS.
Results
During follow up period, 4 patients developed new OVCF (4.8%) and 10 patients showed aggravation of
BMD score (12.1%) in alendronate group. In risedronate group, 4 patients developed new OVCF (5.5%) and 10 patients
were aggravated with BMD scores (13.8%). Statistically, there were no meaningful differences (OVCF; p=0.765, BMD
score; p=0.231) and these results were similar to our previous report.
Conclusion
These results indicate that there are no significant differences in number of newly developed OVCFs
and BMD aggravation in two groups as previous study had shown. |
| Key Words:
OsteoporosisㆍCompression fractureㆍRispedronateㆍAladronateㆍBMD |
|
PDF Links
Download Citation
